• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Active Filters1
Displaying 69-83 of 224 results

1 Power of Attorney: Power of Attorney

Document IPR2019-00207, No. 1 Power of Attorney - Power of Attorney (P.T.A.B. Nov. 6, 2018)
Mail Stop "PATENT BOARD" Patent Trial and Appeal Board U.S. Patent and Trademark Office P.O.
Amneal Pharmaceuticals ofNew York, LLC’S Power ofAttorney Amneal Pharmaceuticals LLC and Pursuant to 37 CPR.
§ 42.10(b), Petitioners, Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York, LLC appoint the following practitioners as their attorneys to transact all business in the United States Patent & Trademark Office associated with an inter partes review of US.
1191 Second Avenue, 10th Floor, Seattle, Washington 98101
cite Cite Document
Analyze

2066 Exhibit: Exhibit 2066 Erick H Turner, How to access and process FDA drug approval packages for use in research, BMJ 2013 served August 30, 2019

Document IPR2019-00207, No. 2066-138 Exhibit - Exhibit 2066 Erick H Turner, How to access and process FDA drug approval packages for use in research, BMJ 2013 served August 30, 2019 (P.T.A.B. De...
See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/257748574 How to access and process FDA drug approval packages for use in research ArticleinBMJ (online) · December 2012 DOI: 10.1136/bmj.f5992
1 author: Erick H Turner Oregon Health and Science University
2,054 Some of the authors of this publication are also working on these related projects: OpenTrialsFDA: Unlocking the FDA trove: Making unbiased clinical trial data accessible View project All content following this page was uploaded by Erick H Turner on 17 July 2016.
How to access and process FDA drug approval packages for use in research FDA databases contain valuable information on unpublished studies, but it can be difficult to find.
This article explains where to look and provides tips on how to make documents easier to use associate professor
cite Cite Document
Analyze

2065 Exhibit: Exhibit 2065 Supplemental Declaration of David W Osborne, PhD served August 10, 2019

Document IPR2019-00207, No. 2065-137 Exhibit - Exhibit 2065 Supplemental Declaration of David W Osborne, PhD served August 10, 2019 (P.T.A.B. Dec. 20, 2019)
I am being compensated for my time in connection with this IPR at my standard legal consultant rate of $500/hr.
for the Development and Optimization of Topical Therapeutic Products, Arlington, VA (Mar. 26, 1990) ("Poulsen"), is a copy of the program for an AAPS/FDA Joint Workshop on Topical Product Development titled Principles and Criteria for the Development and Optimization of Topical Therapeutic Products, which took place March 26-28, 1990, at the Hyatt Regency Crystal City in Arlington, Virginia, and the printed presentation of Boyd J. Poulsen, Ph.D.,
Supplemental Declaration of David W. Osborne, Ph.D. titled "Development Process in Topical Dosage Forms," presented at 10:50 a.m. on Monday, March 26, 1990, as part of that Joint Workshop.
The Joint Workshop was open to the public, provided they paid a fee for attendance.
I confirm that Pages 1-4 of Exhibit 2049 are true and accurate copies of the printed program in advance of the Joint Workshop.
cite Cite Document
Analyze

1076 Exhibit: USPN 9,161,926

Document IPR2019-00207, No. 1076-134 Exhibit - USPN 9,161,926 (P.T.A.B. Nov. 1, 2019)
Subject compositions can be adjusted to optimize the dermal delivery profile of dapsone to effectively treat dermatological conditions and improve the efficiency of pharmaceutical products applied to the skin.
It has been used to treat skin diseases characterized by the abnormal 15 infiltration of neutrophils, such as Dermatitis herpetiformis, linear IgA dermatosis, pustular psoriasis, pyoderma gan grenosum, acne vulgaris, and Sweet's Syndrome.
Skin conditions that can be treated using some com positions, products and methods described herein include, but are not limited to, acne, rosacea, folliculitis, perioral derma titis, photodamage, skin aging, psoriasis, ichtiosis, atopic der- 40 matitis, treatment of chronic wounds, bed sores, keratosis piralis, scars, including surgical and acne scars, sebaceous cysts, inflammatory dermatoses, post inflammatory hyper pigmentation, eczema, xerosis, pruritis, lichen planus, nodu lar prurigo, eczema, and miliaria.
Example 1 Table !lists two formulations (containing equivalent levels of diethylene glycol monoethyl ether) that show the impact of 25 acrylamide/sodium acryloyldimethyltaurate copolymer based thickener on dapsone particle size.
Additional examples containing alternate neutralizer Materials Anti-oxidants and chelating agents such as sodium met abisulfite, citric acid and EDTA were added to formulations to help slow down or completely stop any impurity formation.
cite Cite Document
Analyze

1054 Exhibit: FDA IIG Field Descriptions

Document IPR2019-00207, No. 1054-115 Exhibit - FDA IIG Field Descriptions (P.T.A.B. Nov. 1, 2019)
Log in to see more
cite Cite Document
Analyze

1061 Exhibit: Aczone Gel 75%

Document IPR2019-00207, No. 1061-119 Exhibit - Aczone Gel 75% (P.T.A.B. Nov. 1, 2019)
Log in to see more
cite Cite Document
Analyze

1043 Exhibit: Second Declaration for Dr Michniak Kohn

Document IPR2019-00207, No. 1043-135 Exhibit - Second Declaration for Dr Michniak Kohn (P.T.A.B. Nov. 1, 2019)
Log in to see more
cite Cite Document
Analyze

1073 Exhibit: Kircik 2018 CMS

Document IPR2019-00207, No. 1073-131 Exhibit - Kircik 2018 CMS (P.T.A.B. Nov. 1, 2019)
Log in to see more
cite Cite Document
Analyze

1071 Exhibit: Kircik 2017 CMS

Document IPR2019-00207, No. 1071-129 Exhibit - Kircik 2017 CMS (P.T.A.B. Nov. 1, 2019)
Log in to see more
cite Cite Document
Analyze

1068 Exhibit: Kircik DFD 2016

Document IPR2019-00207, No. 1068-126 Exhibit - Kircik DFD 2016 (P.T.A.B. Nov. 1, 2019)
Log in to see more
cite Cite Document
Analyze

1038 Exhibit: Proposed Joint Pretrial Order Part 1

Document IPR2019-00207, No. 1038-101 Exhibit - Proposed Joint Pretrial Order Part 1 (P.T.A.B. Oct. 18, 2019)
Log in to see more
cite Cite Document
Analyze

1037 Exhibit: Email dated October 8, 2019 from Tyler Liu to trialsusptogov requesting authorization to file a motion for additional discovery

Document IPR2019-00207, No. 1037-100 Exhibit - Email dated October 8, 2019 from Tyler Liu to trialsusptogov requesting authorization to file a motion for additional discovery (P.T.A.B. Oct. 18, 2019)
Log in to see more
cite Cite Document
Analyze

2026 Exhibit: Exhibit 2026 Makrantonaki et al 2011

Document IPR2019-00207, No. 2026-57 Exhibit - Exhibit 2026 Makrantonaki et al 2011 (P.T.A.B. Aug. 9, 2019)
Log in to see more
cite Cite Document
Analyze

2064 Exhibit: Exhibit 2064 Chang et al 2013

Document IPR2019-00207, No. 2064-95 Exhibit - Exhibit 2064 Chang et al 2013 (P.T.A.B. Aug. 9, 2019)
Log in to see more
cite Cite Document
Analyze

2028 Exhibit: Exhibit 2028 Piette et al 2008

Document IPR2019-00207, No. 2028-59 Exhibit - Exhibit 2028 Piette et al 2008 (P.T.A.B. Aug. 9, 2019)
Log in to see more
cite Cite Document
Analyze
<< 1 2 3 4 5 6 7 8 9 ... 14 15 16 >>